Sirona Biochem (TSXV:SBM)

Sirona Biochem Inc.

TSXV:SBM

Advanced Chemistry Platform for Commercial Opportunities in Cosmetics and Pharmaceuticals

​Company Highlights

  • Proven technology platform based on proprietary fluorination chemistry leading to a pipeline of products across a broad range of applications in cosmetics and pharmaceuticals.
  • Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and library of cosmetic compounds.
  • Ongoing royalty payments for compound discoveries, including upcoming royalties on net sales generated by AbbVie product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. Seventeen years duration for TFC-1067 patents.
  • Disruptive proprietary carbohydrate-bonding platform based on 20 years of research and development.
  • Strong worldwide IP portfolio, including North America, European Union and Asia.
  • Cosmetics - Developing disruptive solutions for anti-aging (US$271 billion), cell preservation (US$7.5 billion), and cellulite treatment (US$1.4 billion).
  • Pharmaceutical
    • TFC-039, first-in-market ingestible tablet to treat animal diabetes. In advanced partnership talks with three major animal health companies.
    • Developing antiviral TBD compound for US$36 billion antiviral market.
  • State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong global manufacturing partners for pharmaceutical (Wanbang Pharma, China) and cosmetics (Wuxi AppTec, China).
CEO Interviews
Press Releases
INNspired

Overview

Sirona Biochem Inc. (TSXV:SBM) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and pharmaceutical active ingredients. Its strategy is to license or sell its patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.

Sirona’s technology is based on proprietary fluorination chemistry developed by the company’s wholly owned French subsidiary research and development (R&D) laboratory TFChem. This fluorination chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of pharmaceuticals and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.

Carbohydrate-based molecules are extremely challenging to develop due to their inherent instability. Sirona’s proprietary chemistry technique overcomes that challenge by stabilizing carbohydrates, allowing the company to explore commercial opportunities for these valuable molecules.

Sirona Biochem Inc.

Sirona Biochem Inc. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT


Overview

Sirona Biochem Inc. (TSXV:SBM) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and pharmaceutical active ingredients. Its strategy is to license or sell its patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.

Sirona’s technology is based on proprietary fluorination chemistry developed by the company’s wholly owned French subsidiary research and development (R&D) laboratory TFChem. This fluorination chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of pharmaceuticals and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.

Carbohydrate-based molecules are extremely challenging to develop due to their inherent instability. Sirona’s proprietary chemistry technique overcomes that challenge by stabilizing carbohydrates, allowing the company to explore commercial opportunities for these valuable molecules.

Carbohydrate Molecules

Sirona Biochem’s product line includes an SGLT2 inhibitor for the treatment of type 2 diabetes as well as a range of compounds for skin-care and cell preservation and repair. The company has an exclusive global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), to develop and commercialize topical skin care treatments based on active ingredients derived from certain Sirona patents for TFC-1067 and related family of compounds.

Sirona also has a non-exclusive licensing agreement with Rodan + Fields, a leading skin care brand in the United States, for Sirona’s skin lightening compound TFC-1067, which has been proven safe and effective in clinical trials. Rodan + Fields has since launched its first dark spot corrector product based on TFC-1067.

Sirona Biochem TFC-1067

Sirona is led by a highly experienced team of finance and biotechnology professionals. The company’s chief scientific officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.

Technology Platform

Sirona’s technology platform is based on a fluorination chemistry that stabilizes carbohydrate-based molecules to improve their cosmeceutical and pharmaceutical qualities. Carbohydrate molecules play a central role in cell-to-cell communication and have the ability to interact with proteins, hormones, viruses, toxins and bacteria. In this way, carbohydrates perform a variety of essential biological functions in the human body, making them valuable components for the development of therapeutics and cosmeceuticals.

Technology Platform

While they have broad application potential, carbohydrates are extremely challenging to develop due to their inherent instability. Using chemistry techniques originally developed by TFChem, Sirona has overcome the challenge of stabilizing carbohydrates to develop safer, more effective cosmetic and pharmaceutical active ingredients. This proprietary chemistry method involves strengthening the bond of a carbohydrate molecule by strategically placing fluorine atoms with the molecule. The result is enhanced stability and bioavailability of carbohydrate-based molecules.

Sirona’s fluorination platform has multiple applications. It improves the properties of drugs in development or discontinued drugs that may have been shelved for stability reasons. It can also be used for the development of new products for cosmetics and biological manufacturing. Sirona is exploring multiple commercial opportunities and partnerships for its fluorination technology platform and currently has two streams of product line: cosmetics and pharmaceuticals.

Company Highlights

  • Proven technology platform based on proprietary fluorination chemistry leading to a pipeline of products across a broad range of applications in cosmetics and pharmaceuticals.
  • Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and library of cosmetic compounds.
  • Ongoing royalty payments for compound discoveries, including upcoming royalties on net sales generated by AbbVie product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. Seventeen years duration for TFC-1067 patents.
  • Disruptive proprietary carbohydrate-bonding platform based on 20 years of research and development.
  • Strong worldwide IP portfolio, including North America, European Union and Asia.
  • Cosmetics - Developing disruptive solutions for anti-aging (US$271 billion), cell preservation (US$7.5 billion), and cellulite treatment (US$1.4 billion).
  • Pharmaceutical
    • TFC-039, first-in-market ingestible tablet to treat animal diabetes. In advanced partnership talks with three major animal health companies.
    • Developing antiviral TBD compound for US$36 billion antiviral market.
  • State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong global manufacturing partners for pharmaceutical (Wanbang Pharma, China) and cosmetics (Wuxi AppTec, China).

The Conversation (0)
Sirona Biochem Inc.

Sirona Biochem Inc. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

×